Tuesday, May 30, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Defense + Military

Army Developing Implantable Sustained-Release Malaria Countermeasure

by Global Biodefense Staff
May 13, 2018
Malaria Infected Red Blood Cells

The Experimental Therapeutics (ET) Branch of the Walter Reed Army Institute of Research (WRAIR) focuses on the development of new drugs to prevent and treat malaria, leishmaniosis, antibiotic-resistant bacteria, and other infectious disease threats to US Service members.

The ET branch is currently attempting to develop anti-malaria prophylactic drug infused implantable matrices that have sustained release.

On behalf of WRAIR, the U.S. Army Medical Research Acquisition Activity (USAMRAA) has announced intentions to negotiate a sole source contract with the Southwest Research Institute for the production of customized subdermal implants with a specific combination of a drug of choice and ethylene-vinyl acetate (EVA) copolymer using the patented technology ProNeura.

The combination of atovaquone/proguanil (Malarone®) and doxycycline are the only FDA-approved prophylactic drugs for malaria prevention. Because of the relatively short half-lives of the drugs, successful prevention of malaria is highly dependent on compliance with a daily oral dosing regimen.

The FDA approved long-term drug delivery platform, ProNeura, is a matrix of EVA which is readily available to modify this drug administration schedule. By incorporating long term release of FDA-approved antimalarial drugs in a drug matrix of EVA, drug rods can be implanted in service members, which frees the deployed service members from adhering to a daily oral drug dosing schedule and should protect from malaria for the entire deployment after implant insertion.

The combination of atovaquone/proguanil and doxycycline in subdermal implant form will be tested for long-term prophylactic efficacy to replace the current orally administered drug regimens.

Source: FBO.gov

See also:

  • Titan Pharmaceuticals, WRAIR Collaborate to Evaluate Proneura Antimalarial Implants
  • Military Recruiting Volunteers for Human Trials of Malaria Vaccines
  • In Pictures: Decades of Navy Efforts to Combat Malaria
Tags: MalariaWRAIR

Related Posts

Vials of finished vaccines
Funding News

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics
Industry News

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023
Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC